Monday, September 21, 2020 11:18:41 AM
"The global spread of coronavirus has meant an increased focus on pharmaceutical companies that are developing Covid-19 related products, Sorrento being one of them with its COVI-Guard antibody. The recent development of FDA nod for phase 1 trial is important for Sorrento, with its objective to expand the study to a large trial and potentially apply for emergency use authorization from the U.S. FDA. Now, the company in a press release stated that its application for EUA can be as early as December. The other companies developing the antibody are expected to file for regulatory nod only towards the end of Q4 or later next year. If Sorrento were to be the first company with its antibody in the market via EUA, it would result in a meaningful appreciation in the stock price from the current levels, in our view. That said, the investors willing to take such risk should also weigh in the possibility of the company not able to secure the EUA."
https://www.google.com/amp/s/www.forbes.com/sites/greatspeculations/2020/09/21/sorrento-therapeutics-stock-is-an-interesting-pick-at-9/amp/
"The refusal of the real is the number one dogma of our time" Rene Girard
Recent SRNE News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 01:51:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 09:25:07 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/07/2023 08:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 10:01:54 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 10:26:26 AM
- Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the A • GlobeNewswire Inc. • 06/05/2023 01:00:00 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM